First Time Loading...

Ucb SA
OTC:UCBJF

Watchlist Manager
Ucb SA Logo
Ucb SA
OTC:UCBJF
Watchlist
Price: 126.05 USD Market Closed
Updated: Apr 19, 2024

Intrinsic Value

UCB SA engages in the research and development biopharmaceuticals products. [ Read More ]

The intrinsic value of one UCBJF stock under the Base Case scenario is 98.48 USD. Compared to the current market price of 126.05 USD, Ucb SA is Overvalued by 22%.

Key Points:
UCBJF Intrinsic Value
Base Case
98.48 USD
Overvaluation 22%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ucb SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling UCBJF stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Ucb SA

Provide an overview of the primary business activities
of Ucb SA.

What unique competitive advantages
does Ucb SA hold over its rivals?

What risks and challenges
does Ucb SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ucb SA.

Provide P/S
for Ucb SA.

Provide P/E
for Ucb SA.

Provide P/OCF
for Ucb SA.

Provide P/FCFE
for Ucb SA.

Provide P/B
for Ucb SA.

Provide EV/S
for Ucb SA.

Provide EV/GP
for Ucb SA.

Provide EV/EBITDA
for Ucb SA.

Provide EV/EBIT
for Ucb SA.

Provide EV/OCF
for Ucb SA.

Provide EV/FCFF
for Ucb SA.

Provide EV/IC
for Ucb SA.

Show me price targets
for Ucb SA made by professional analysts.

What are the Revenue projections
for Ucb SA?

How accurate were the past Revenue estimates
for Ucb SA?

What are the Net Income projections
for Ucb SA?

How accurate were the past Net Income estimates
for Ucb SA?

What are the EPS projections
for Ucb SA?

How accurate were the past EPS estimates
for Ucb SA?

What are the EBIT projections
for Ucb SA?

How accurate were the past EBIT estimates
for Ucb SA?

Compare the revenue forecasts
for Ucb SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ucb SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ucb SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ucb SA compared to its peers.

Compare the P/E ratios
of Ucb SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Ucb SA with its peers.

Analyze the financial leverage
of Ucb SA compared to its main competitors.

Show all profitability ratios
for Ucb SA.

Provide ROE
for Ucb SA.

Provide ROA
for Ucb SA.

Provide ROIC
for Ucb SA.

Provide ROCE
for Ucb SA.

Provide Gross Margin
for Ucb SA.

Provide Operating Margin
for Ucb SA.

Provide Net Margin
for Ucb SA.

Provide FCF Margin
for Ucb SA.

Show all solvency ratios
for Ucb SA.

Provide D/E Ratio
for Ucb SA.

Provide D/A Ratio
for Ucb SA.

Provide Interest Coverage Ratio
for Ucb SA.

Provide Altman Z-Score Ratio
for Ucb SA.

Provide Quick Ratio
for Ucb SA.

Provide Current Ratio
for Ucb SA.

Provide Cash Ratio
for Ucb SA.

What is the historical Revenue growth
over the last 5 years for Ucb SA?

What is the historical Net Income growth
over the last 5 years for Ucb SA?

What is the current Free Cash Flow
of Ucb SA?

Financials

Balance Sheet Decomposition
Ucb SA

Current Assets 3.4B
Cash & Short-Term Investments 1.1B
Receivables 1.3B
Other Current Assets 1.1B
Non-Current Assets 12.1B
Long-Term Investments 210m
PP&E 1.6B
Intangibles 9.5B
Other Non-Current Assets 804m
Current Liabilities 2.6B
Accounts Payable 2.3B
Other Current Liabilities 303m
Non-Current Liabilities 3.9B
Long-Term Debt 3B
Other Non-Current Liabilities 952m
Efficiency

Earnings Waterfall
Ucb SA

Revenue
5.3B EUR
Cost of Revenue
-1.7B EUR
Gross Profit
3.5B EUR
Operating Expenses
-3B EUR
Operating Income
514m EUR
Other Expenses
-171m EUR
Net Income
343m EUR

Free Cash Flow Analysis
Ucb SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

UCBJF Profitability Score
Profitability Due Diligence

Ucb SA's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive Revenue Growth Forecast
Positive Operating Income
53/100
Profitability
Score

Ucb SA's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

UCBJF Solvency Score
Solvency Due Diligence

Ucb SA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Average Altman Z-Score
48/100
Solvency
Score

Ucb SA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

UCBJF Price Targets Summary
Ucb SA

Wall Street analysts forecast UCBJF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for UCBJF is 131.16 USD with a low forecast of 79.71 USD and a high forecast of 183.64 USD.

Lowest
Price Target
79.71 USD
37% Downside
Average
Price Target
131.16 USD
4% Upside
Highest
Price Target
183.64 USD
46% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

UCB Price
Ucb SA

1M 1M
+12%
6M 6M
+67%
1Y 1Y
+42%
3Y 3Y
+50%
5Y 5Y
+79%
10Y 10Y
+128%
Annual Price Range
121
52w Low
65.78
52w High
121
Price Metrics
Average Annual Return 3.89%
Standard Deviation of Annual Returns 20.79%
Max Drawdown -33%
Shares Statistics
Market Capitalization 23B EUR
Shares Outstanding 189 776 992
Percentage of Shares Shorted
N/A

UCB Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Ucb SA Logo
Ucb SA

Country

Belgium

Industry

Pharmaceuticals

Market Cap

23B USD

Dividend Yield

1.17%

Description

UCB SA engages in the research and development biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 8,615 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Contact

BRUXELLES-CAPITALE
Anderlecht
Allee de la Recherche, 60
+3225599999.0
https://www.ucb.com

IPO

1987-01-02

Employees

8 615

Officers

CEO & Executive Director
Mr. Jean-Christophe Tellier
Executive VP, CFO & Chief Corporate Development
Ms. Sandrine Dufour CFA
Executive Vice President of Supply & Technology Solutions
Dr. Kirsten Lund-Jurgensen Ph.D.
Executive VP & Chief Scientific Officer
Dr. Dhavalkumar D. Patel M.D., Ph.D.
Executive VP & General Counsel
Ms. Denelle J. Waynick Johnson J.D.
Executive VP & Chief Human Resources Officer
Mr. Jean-Luc Fleurial
Show More
Executive VP & Chief Medical Officer
Prof. Iris Low-Friedrich
Executive VP of Immunology Solutions & Head of US
Mr. Emmanuel Caeymaex
Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions
Ms. Caroline Vancoillie
Head of Investor Relations
Antje Witte
Show Less

See Also

Discover More
What is the Intrinsic Value of one UCBJF stock?

The intrinsic value of one UCBJF stock under the Base Case scenario is 98.48 USD.

Is UCBJF stock undervalued or overvalued?

Compared to the current market price of 126.05 USD, Ucb SA is Overvalued by 22%.